Coherus Posts 94% Pegfilgrastim Margin Ahead Of Royalties To Amgen

 
• By Aidan Fry
  
Margin
Coherus believes it can maintain US pegfilgrastim gross margins above 90%, even while paying royalties to Amgen • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products